Clinical Trials Logo

Clinical Trial Summary

This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of the target lesion followed by surgical tumor excision 60 days post-treatment.


Clinical Trial Description

The study will enroll healthy adult subjects with confirmed low-risk (superficial and nodular) BCC lesion(s) by biopsy, excluding BCCs located on the face, neck, scalp, axilla, hands, feet, and genitals not exceeding 1.5 cm. Macrophotography of all study BCCs will be captured and clinically assessed by the site investigator for characterization of healing and scar appearance prior to and post-surgical excision. All subjects will be followed at 3, 7, 14, 30 and 60-days post-CellFX procedure and at 14, 30 and 60-days post-excision. Adverse events will be documented. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04918381
Study type Interventional
Source Pulse Biosciences, Inc.
Contact
Status Completed
Phase N/A
Start date June 2, 2021
Completion date July 22, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04552990 - Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma Phase 2
Recruiting NCT05859074 - A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer Phase 1
Recruiting NCT05329792 - L19IL2/L19TNF in Skin Cancer Patients Phase 2
Recruiting NCT04570683 - Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas Early Phase 1
Recruiting NCT06279143 - The Diagnostic Accuracy of Advanced Imaging in Identifying Suspected Skin Cancer (Basal Cell Carcinoma) Around the Eyes